Radius Health Inc

About Radius

Radius Health Cambridge MassRadius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.

Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market. The Company's lead investigational drug product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the potential prevention of fractures in post-menopausal women at risk of fracture from osteoporosis.

Radius' clinical portfolio also includes a new investigational oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader, or SERD, in development at higher doses for the potential treatment of breast cancer brain metastases, and at lower doses as a selective estrogen-receptor modulator, or SERM, for the potential treatment of vasomotor symptoms such as hot flashes.